Literature DB >> 32016073

Non-selective beta blockers in cirrhosis: time to extend the indications?

Dev Katarey1, Rajiv Jalan1.   

Abstract

Entities:  

Year:  2019        PMID： 32016073      PMCID： PMC6976476          DOI： 10.21037/atm.2019.09.56

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  9 in total

1.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

2.  Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.

Authors:  Rajeshwar P Mookerjee; Marco Pavesi; Karen Louise Thomsen; Gautam Mehta; Jane Macnaughtan; Flemming Bendtsen; Minneke Coenraad; Jan Sperl; Pere Gines; Richard Moreau; Vicente Arroyo; Rajiv Jalan
Journal:  J Hepatol       Date:  2015-10-28       Impact factor: 25.083

Review 3.  Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.

Authors:  Mauro Bernardi; Richard Moreau; Paolo Angeli; Bernd Schnabl; Vicente Arroyo
Journal:  J Hepatol       Date:  2015-07-17       Impact factor: 25.083

4.  β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.

Authors:  Càndid Villanueva; Agustín Albillos; Joan Genescà; Joan C Garcia-Pagan; José L Calleja; Carles Aracil; Rafael Bañares; Rosa M Morillas; María Poca; Beatriz Peñas; Salvador Augustin; Juan G Abraldes; Edilmar Alvarado; Ferran Torres; Jaume Bosch
Journal:  Lancet       Date:  2019-03-22       Impact factor: 79.321

5.  Compensated cirrhosis: natural history and prognostic factors.

Authors:  P Ginés; E Quintero; V Arroyo; J Terés; M Bruguera; A Rimola; J Caballería; J Rodés; C Rozman
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

Review 6.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies.

Authors:  Laura Pimpin; Helena Cortez-Pinto; Francesco Negro; Emily Corbould; Jeffrey V Lazarus; Laura Webber; Nick Sheron
Journal:  J Hepatol       Date:  2018-05-17       Impact factor: 25.083

7.  Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

Authors:  Cristina Ripoll; Roberto Groszmann; Guadalupe Garcia-Tsao; Norman Grace; Andrew Burroughs; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; Robert Makuch; David Patch; Daniel S Matloff; Jaime Bosch
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

Review 8.  Inflammation and portal hypertension - the undiscovered country.

Authors:  Gautam Mehta; Thierry Gustot; Rajeshwar P Mookerjee; Juan Carlos Garcia-Pagan; Michael B Fallon; Vijay H Shah; Richard Moreau; Rajiv Jalan
Journal:  J Hepatol       Date:  2014-03-18       Impact factor: 25.083

9.  Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.

Authors:  Haesuk Park; Wei Wang; Linda Henry; David R Nelson
Journal:  Hepatology       Date:  2019-02-10       Impact factor: 17.425
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.